TACE + vitamin K treatment

Efficacy and safety of TACE and vitamin K combination treatment against hepatocellular carcinoma-Open label, randomized, phase 2 study - TACEVK

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051180115

Enrollment

200

Registered

2019-03-11

Start date

2017-04-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma (HCC)

Interventions

daily dosing of vitamin K2(45mg) since one day before TACE to 28 days after

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients indicated to transarterial chemoembolization (TACE) against hepatocellular carcinoma, ECOG PS 0 or 1, Child-Pugh score 5-7, obtained written informed consent

Exclusion criteria

Exclusion criteria: Patients who underwent previous TACE greater than twice, patients with warfarin dosing, patients who have been given vitamin K before the enrollment

Design outcomes

Primary

Measure	Time frame
treatment effect of TACE	—

Secondary

Measure	Time frame
Safety	—

Contacts

Public ContactYoshimichi Haruna

3-1-56 Bandaihigashi Sumiyoshi-ku Osaka, Japan

apple-123-grape@ab.auone-net.jp+81-6-6692-1201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026